Markets
Articles published by Biogen Inc.

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
May 15, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB


Biogen Appoints Adam Keeney as Head of Corporate Development
April 04, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
March 30, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB







Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 27, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB


Lecanemab Receives Priority Review Status in Japan
January 29, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB





FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
December 09, 2022
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB

European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
December 05, 2022
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB




Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
October 17, 2022
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB


Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
September 30, 2022
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.